Tumor-specific antigen TSP70 and application thereof

A tumor antigen, non-small cell lung cancer technology, applied in the field of biomedicine, can solve the problems of no targeted imaging technology reports, and achieve the effect of high expression specificity and high expression positive rate

Inactive Publication Date: 2017-12-01
JIANGSU CODE BIOMEDICAL TECH CO LTD
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Thyroid transcription factor-1 (TTF-1) and Napsin A are well known as markers of lung adenocarcinoma, but targeted imaging techniques for these molecules have not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Tumor-specific antigen TSP70 and application thereof
  • Tumor-specific antigen TSP70 and application thereof
  • Tumor-specific antigen TSP70 and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0050] Example 1 Isolation and purification of TSP70 protein

[0051] 1. Preparation of human lung cancer cell line SPC-A1 cell lysate

[0052] 1) Cultivate SPC-A1 cells, discard the SPC-A1 cell culture medium, wash twice with Hanks solution, trypsinize for 2 minutes, add culture medium to resuspend the cells, and transfer the cell suspension to a 15mL (or 50mL) centrifuge tube , centrifuge at 1000rpm for 5 minutes, and discard the supernatant;

[0053] 2) Wash the cells once with pre-cooled PBS, centrifuge at 1000rpm for 5 minutes; transfer the cells to a 1.5mL EP tube, wash with PBS, and centrifuge at 12000pm for 5 minutes;

[0054] 3) Thaw the IP cell lysate on ice in advance. Take an appropriate amount of lysate (50uL / 10 6 cells), add 100mM protease inhibitors PMSF, PHI and PI in a ratio of 1:100;

[0055] 4) Add the lysate to the cell mass, and mix by pipetting;

[0056] 5) Incubate on ice for 30 minutes, vortex every 5 minutes;

[0057] 6) Centrifuge at 12000pm at ...

Embodiment 2

[0072] SDS-PAGE electrophoresis and Western blot identification of embodiment 2 TSP70 protein

[0073] 1 SDS-PAGE determination of protein molecular weight

[0074] The concentration of the separating gel is 12%, and the concentration of the stacking gel is 5%. After the sample is boiled for 3 minutes, the sample is added for electrophoresis, and the standard molecular weight is added as a control. The starting voltage is 80V, the sample is concentrated into a line and then increased to 120V after entering the separation gel, the total electrophoresis is about 2.5h, and Coomassie brilliant blue staining after stripping the gel. Electrophoresis results see figure 1 After electrophoresis, draw a molecular weight standard curve on semi-logarithmic coordinate paper according to the molecular weight of the standard protein and its relative mobility, and then find out that its molecular weight is 70Kda from the standard curve according to the relative mobility of the protein to be...

Embodiment 3

[0077] Example 3 Determination of the amino acid sequence of the TSP70 protein

[0078] 1. Treat with 8mol / L urea to split the polypeptide chain.

[0079] 2. Determine the number of polypeptide chains by determining the relationship between the molar number of terminal amino acid residues and the molecular weight of the protein.

[0080] 3. In the presence of 8mol / L urea, treat with excess β-mercaptoethanol to break the disulfide bond and reduce it to sulfhydryl.

[0081] 4. Determine the amino acid composition of each polypeptide chain, and calculate the molecular ratio of the amino acid composition.

[0082] 5. Analysis of the N-terminal and C-terminal ends of the polypeptide chains.

[0083] 6. The polypeptide chain is broken into multiple peptides and separated.

[0084] 7. Determine the amino acid sequence of each peptide.

[0085] 8. Determine the order of the peptides in the polypeptide chain, and use the overlapping and overlapping of the amino acid sequences of tw...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
thicknessaaaaaaaaaa
Login to view more

Abstract

The invention relates to a tumor-specific antigen TSP70 and an application thereof. The tumor-specific antigen TSP70 has an amino acid sequence shown in SEQ ID No. 1. The invention also provides the application of the tumor-specific antigen TSP70 of non-small-cell lung cancers, pancreatic cancers, ovarian cancers, mammary cancers and the like in preparation of diagnostic reagents for tumors such as the non-small-cell lung cancers, the pancreatic cancers, the ovarian cancers and the mammary cancers. The invention provides the novel tumor-specific antigen TSP70. The antigen has high expression positive rate in tumor cells of the non-small-cell lung cancers, the pancreatic cancers, the ovarian cancers, the mammary cancers and the like of human and also has high expression specificity; proven by an immuno-electron microscope, a protein of the TSP70 is located in cell membranes, cytoplasm and cell nuclei of cells; and the antigen can be used for preparing the diagnostic reagents for the tumors such as the non-small-cell lung cancers, the pancreatic cancers, the ovarian cancers and the mammary cancers as a standard substance and can also be used for preparing drugs for treating or preventing the tumors such as the non-small-cell lung cancers, the pancreatic cancers, the ovarian cancers and the mammary cancers.

Description

technical field [0001] The invention belongs to the field of biomedicine and relates to a tumor-specific antigen TSP70 and its application. Background technique [0002] Non-small cell lung cancer, pancreatic cancer, ovarian cancer and breast cancer are the most common malignant tumors with high malignant degree and high mortality in the world today. With the continuous growth of population and the aggravation of population aging, coupled with changes in lifestyle, society, economy, and environment, the incidence and mortality of malignant tumors, especially lung cancer, are on the rise. About 1.61 million lung cancer cases are diagnosed each year, accounting for 12.7% of malignant tumors, and about 1.38 million lung cancer-related deaths account for 18.2% of cancer-related deaths. Lung cancer is also one of the most common malignant tumors in my country, and its morbidity and mortality rank first in most areas of my country. Non-small cell lung cancer (NSCLC) accounts for...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K14/47C07K16/18G01N33/68G01N33/574G01N33/577A61K49/00A61K49/04A61K39/00A61P35/00
CPCA61K39/00A61K49/0058A61K49/04C07K14/4748C07K16/18G01N33/57415G01N33/57423G01N33/57438G01N33/57449G01N33/57488G01N33/577G01N33/68G01N2500/04
Inventor 潘世扬徐建
Owner JIANGSU CODE BIOMEDICAL TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap